The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Broyan T.S.

Ryazan State Medical University

Kalinin R.E.

Pavlov Ryazan State Medical University

Suchkov I.A.

Pavlov Ryazan State Medical University

Mzhavanadze N.D.

Pavlov Ryazan State Medical University

The role of endothelium and certain parameters of hemostasis for thrombotic complications in endovascular surgery of coronary arteries

Authors:

Broyan T.S., Kalinin R.E., Suchkov I.A., Mzhavanadze N.D.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2025;(6): 89‑97

DOI: 10.17116/hirurgia202506189

Read: 825 times

Buy for 300₽
Contact the author
Table of contents

THE ROLE OF ENDOTHELIUM AND CERTAIN PARAMETERS OF HEMOSTASIS FOR THROMBOTIC COMPLICATIONS IN ENDOVASCULAR SURGERY OF CORONARY ARTERIES
THE ROLE OF ENDOTHELIUM AND CERTAIN PARAMETERS OF HEMOSTASIS FOR THROMBOTIC COMPLICATIONS IN ENDOVASCULAR SURGERY OF CORONARY ARTERIES

To cite this article:

Broyan TS, Kalinin RE, Suchkov IA, Mzhavanadze ND. The role of endothelium and certain parameters of hemostasis for thrombotic complications in endovascular surgery of coronary arteries. Pirogov Russian Journal of Surgery. 2025;(6):89‑97. (In Russ.)
https://doi.org/10.17116/hirurgia202506189

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Intravascular imaging and physiological asse­ssment of coro­nary blood flow for treatment stra­tegy in patients with acute coro­nary syndrome. Analysis of Russian regi­stry of intravascular imaging and physiological methods in 2021—2022. Russian Cardiology Bulletin. 2024;(3):43-52
Prediction of no-reflow phenomenon in endo­vascular treatment of patients with acute ST segment elevation myocardial infa­rction. Russian Cardiology Bulletin. 2024;(4):52-58
Analysis of risk factors asso­ciated with ischemic stroke in the setting of Ph-negative myeloproliferative diseases. Russian Journal of Preventive Medi­cine. 2025;(1):50-56
Abstract:

Cardiovascular diseases are still the main cause of death despite various measures in all countries around the world. Coronary artery disease is the most common cardiovascular disease following atheromatous lesions of coronary arteries. Coronary artery disease describes a range of clinical disorders from asymptomatic atherosclerosis and stable angina to acute coronary syndrome. One of the most effective methods of surgical treatment for coronary artery disease is percutaneous coronary intervention (PCI). The number of PCIs has actively increased in recent years. Thrombotic events in various vascular basins are serious complications of PCI. This article describes the role of endothelium, platelet activation, and hemostatic parameters in occurrence of thrombotic complications after PCI.

Keywords:

coronary artery stenting
vWF
FVIII
ADAMTS13
thrombosis

Authors:

Broyan T.S.

Ryazan State Medical University

Kalinin R.E.

Pavlov Ryazan State Medical University

Suchkov I.A.

Pavlov Ryazan State Medical University

Mzhavanadze N.D.

Pavlov Ryazan State Medical University

Received:

16.12.2024

Accepted:

15.02.2025

Close metadata

References:

  1. Malik TF, Tivakaran VS. Percutaneous Transluminal Coronary Angioplasty. 2023 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
  2. Rawlins J, Wilkinson J, Curzen N. Evidence for Benefit of Percutaneous Coronary Intervention for Chronically Occluded Coronary Arteries (CTO) — Clinical and Health Economic Outcomes. Interv Cardiol. 2014;9(3):190-194.  https://doi.org/10.15420/icr.2014.9.3.190
  3. Singh RS, Saini BS, Sunkaria RK. Detection of coronary artery disease by reduced features and extreme learning machine. Clujul Med. 2018;91(2):166-175.  https://doi.org/10.15386/cjmed-882
  4. Lee KW, Blann AD, Lip GY. Plasma markers of endothelial damage/dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes. Thromb Haemost. 2005;94(5):1077-1003. https://doi.org/10.1160/TH05-03-0179
  5. Liu KL, Lin SM, Chang CH, Chen YC, Chu PH. Plasma angiopoietin-1 level, left ventricular ejection fraction, and multivessel disease predict development of 1-year major adverse cardiovascular events in patients with acute ST elevation myocardial infarction — a pilot study. Int J Cardiol. 2015;182:155-160.  https://doi.org/10.1016/j.ijcard.2014.12.172
  6. Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201 Suppl 1:S1-7.  https://doi.org/10.1016/S0167-5273(15)31026-3
  7. Silvain J, Collet JP, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, Cayla G, Pena A, Brugier D, Barthelemy O, Montalescot G, Weisel JW. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011;57(12):1359-1367. https://doi.org/10.1016/j.jacc.2010.09.077
  8. Wilcox JN, Noguchi S, Casanova J. Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 2003;23(1):136-141.  https://doi.org/10.1161/01.atv.0000043418.84185.3c
  9. Ardissino D, Merlini PA, Bauer KA, Bramucci E, Ferrario M, Coppola R, Fetiveau R, Lucreziotti S, Rosenberg RD, Mannucci PM. Thrombogenic potential of human coronary atherosclerotic plaques. Blood. 2001;98(9):2726-2729. https://doi.org/10.1182/blood.v98.9.2726
  10. Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, Govers-Riemslag JW, Hamulyák K, Hackeng TM, Daemen MJ, ten Cate H, Spronk HM. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122(8):821-830.  https://doi.org/10.1161/CIRCULATIONAHA.109.907121
  11. Shnerb Ganor R, Harats D, Schiby G, Gailani D, Levkovitz H, Avivi C, Tamarin I, Shaish A, Salomon O. Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice. Arterioscler Thromb Vasc Biol. 2016;36(3):475-481.  https://doi.org/10.1161/ATVBAHA.115.306954
  12. Vorlova S, Koch M, Manthey HD, Cochain C, Busch M, Chaudhari SM, Stegner D, Yepes M, Lorenz K, Nolte MW, Nieswandt B, Zernecke A. Coagulation factor XII induces pro-inflammatory cytokine responses in macrophages and promotes atherosclerosis in mice. Thromb Haemost. 2017;117(1):176-187.  https://doi.org/10.1160/TH16-06-0466
  13. Nickel KF, Long AT, Fuchs TA, Butler LM, Renné T. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases. Arterioscler Thromb Vasc Biol. 2017;37(1):13-20.  https://doi.org/10.1161/ATVBAHA.116.308595
  14. Marcu R, Choi YJ, Xue J, Fortin CL, Wang Y, Nagao RJ, Xu J, MacDonald JW, Bammler TK, Murry CE, Muczynski K, Stevens KR, Himmelfarb J, Schwartz SM, Zheng Y. Human Organ-Specific Endothelial Cell Heterogeneity. iScience. 2018;4:20-35.  https://doi.org/10.1016/j.isci.2018.05.003
  15. Yang X, Chang Y, Wei W. Endothelial Dysfunction and Inflammation: Immunity in Rheumatoid Arthritis. Mediators Inflamm. 2016;2016:6813016. https://doi.org/10.1155/2016/6813016
  16. Neubauer K, Zieger B. Endothelial cells and coagulation. Cell Tissue Res. 2022;387(3):391-398.  https://doi.org/10.1007/s00441-021-03471-2
  17. De Pablo-Moreno JA, Serrano LJ, Revuelta L, Sánchez MJ, Liras A. The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V. Int J Mol Sci. 2022;23(15):8283. https://doi.org/10.3390/ijms23158283
  18. Anastasiou G, Gialeraki A, Merkouri E, Politou M, Travlou A. Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis. Blood Coagul Fibrinolysis. 2012;23(1):1-10.  https://doi.org/10.1097/MBC.0b013e32834cb271
  19. Bauer KA, Rosenberg RD. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol. 1991;28(1):10-18. 
  20. Kalinin RE, Suchkov IA, Povarov VO, Mzhavanadze ND, Zhurina ON. Sostoyanie sistemy gemostaza pacientov s bradikardiyami posle implantacii dvuhkamernyh elektrokardiostimulyatorov. Rossijskij mediko-biologicheskij vestnik imeni akademika I.P. Pavlova. 2021;29(4):497-504. (In Russ.). https://doi.org/10.17816/PAVLOVJ79285
  21. Girard TJ, Grunz K, Lasky NM, Malone JP, Broze GJ Jr. Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. J Thromb Haemost. 2018;16(11):2246-2257. https://doi.org/10.1111/jth.14288
  22. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003;17 Suppl 1:S1-5.  https://doi.org/10.1016/s0268-960x(03)90000-2
  23. Kalinin RE, Suchkov IA, Klimentova EA, Afenov MR, Surov IYu. Vliyanie primeneniya kombinirovannoj antioksidantnoj terapii na rezul’taty endovaskulyarnogo lecheniya pacientov s obliteriruyushchim aterosklerozom arterij nizhnih konechnostej. Nauka molodyh (Eruditio Juvenium). 2022;10(4):401-412. (In Russ.). https://doi.org/10.23888/HMJ2022104401-412
  24. Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Tsioufis K, Tousoulis D. Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches. Int J Mol Sci. 2022;23(6):3301. https://doi.org/10.3390/ijms23063301
  25. Naß J, Terglane J, Gerke V. Weibel Palade Bodies: Unique Secretory Organelles of Endothelial Cells that Control Blood Vessel Homeostasis. Front Cell Dev Biol. 2021;9:813995. https://doi.org/10.3389/fcell.2021.813995
  26. Yasar SJ, Abdullah O, Fay W, Balla S. Von Willebrand factor revisited. J Interv Cardiol. 2018;31(3):360-367.  https://doi.org/10.1111/joic.12478
  27. Koloskov AV, Mangushlo AA. Metalloprotease ADAMTS-13. Russian journal of hematology and transfusiology. 2019;64(4):471-482. (In Russ.). https://doi.org/10.35754/0234-5730-2019-64-4-471-482
  28. Mazurkiewicz-Pisarek A, Płucienniczak G, Ciach T, Płucienniczak A. The factor VIII protein and its function. Acta Biochim Pol. 2016;63(1):11-16.  https://doi.org/10.18388/abp.2015_1056
  29. Takeyama M, Nogami K, Sasai K, Furukawa S, Shima M. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex. Thromb Haemost. 2018;118(5):830-841.  https://doi.org/10.1055/s-0038-1637745
  30. Orfeo T, Elsman R, Gissel M, Mann KG, Butenas S. Activation, activity and inactivation of factor VIII in factor VIII products. Haemophilia. 2016;22(3):462-473.  https://doi.org/10.1111/hae.12872
  31. Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019-2028. https://doi.org/10.1182/blood-2014-06-528406
  32. Fan M, Wang X, Peng X, Feng S, Zhao J, Liao L, Zhang Y, Hou Y, Liu J. Prognostic value of plasma von Willebrand factor levels in major adverse cardiovascular events: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2020;20(1):72.  https://doi.org/10.1186/s12872-020-01375-7
  33. Miura M, Kaikita K, Matsukawa M, Soejima K, Fuchigami S, Miyazaki Y, Ono T, Uemura T, Tsujita K, Hokimoto S, Sumida H, Sugiyama S, Matsui K, Yamabe H, Ogawa H. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost. 2010;103(3):623-629.  https://doi.org/10.1160/TH09-08-0568
  34. Wang X, Zhao J, Zhang Y, Xue X, Yin J, Liao L, Xu C, Hou Y, Yan S, Liu J. Kinetics of plasma von Willebrand factor in acute myocardial infarction patients: a meta-analysis. Oncotarget. 2017;8(52):90371-90379. https://doi.org/10.18632/oncotarget.20091
  35. Kalinin RE, Suchkov IA, Mzhavanadze ND, Zhurina ON, Klimentova EA, Povarov VO. Faktor fon Villebranda pri vypolnenii invazivnyh vmeshatel’stv u bol’nyh s perifericheskim aterosklerozom. Rossijskij mediko-biologicheskij vestnik imeni akademika I.P. Pavlova. 2021;2(3):389-396. (In Russ.). https://doi.org/10.17816/PAVLOVJ79099
  36. Qu L, Jiang M, Qiu W, Lu S, Zhao Y, Xia L, Ruan C, Zhao Y. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction. Clin Appl Thromb Hemost. 2016;22(3):252-259.  https://doi.org/10.1177/1076029615583347
  37. Dong J, Li YJ, Yang ZK, Xu R. Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients. Perit Dial Int. 2014;34(7):706-713.  https://doi.org/10.3747/pdi.2012.00004
  38. Al-Masri AA, Habib SS, Hersi A, Al Zamil H. Effect of Acute Myocardial Infarction on a Disintegrin and Metalloprotease with Thrombospondin Motif 13 and Von Willebrand Factor and Their Relationship with Markers of Inflammation. Int J Vasc Med. 2020;2020:4981092. https://doi.org/10.1155/2020/4981092
  39. Reardon B, Pasalic L, Favaloro EJ. The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease. J Cardiovasc Dev Dis. 2021;8(9):115.  https://doi.org/10.3390/jcdd8090115
  40. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767-776.  https://doi.org/10.1084/jem.20051732
  41. Sonneveld MA, Kavousi M, Ikram MA, Hofman A, Rueda Ochoa OL, Turecek PL, Franco OH, Leebeek FW, de Maat MP. Low ADAMTS-13 activity and the risk of coronary heart disease — a prospective cohort study: the Rotterdam Study. J Thromb Haemost. 2016;14(11):2114-2120. https://doi.org/10.1111/jth.13479
  42. Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thromb Res. 2010;125(1):61-66.  https://doi.org/10.1016/j.thromres.2009.03.008
  43. Maino A, Siegerink B, Lotta LA, Crawley JT, le Cessie S, Leebeek FW, Lane DA, Lowe GD, Peyvandi F, Rosendaal FR. Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis. J Thromb Haemost. 2015;13(8):1396-1404. https://doi.org/10.1111/jth.13032
  44. Ye Z, Zheng J. Verification of the Role of ADAMTS13 in the Cardiovascular Disease Using Two-Sample Mendelian Randomization. Front Genet. 2021;12:660989. https://doi.org/10.3389/fgene.2021.660989
  45. Wolhuter K, Kong SMY, Stanley CP, Kovacic JC. The Role of Oxidants in Percutaneous Coronary Intervention-Induced Endothelial Dysfunction: Can We Harness Redox Signaling to Improve Clinical Outcomes? Antioxid Redox Signal. 2023;38(13-15):1022-1040. https://doi.org/10.1089/ars.2022.0204
  46. Tucker B, Vaidya K, Cochran BJ, Patel S. Inflammation during Percutaneous Coronary Intervention-Prognostic Value, Mechanisms and Therapeutic Targets. Cells. 2021;10(6):1391. https://doi.org/10.3390/cells10061391
  47. Su LC, Xu H, Tran RT, Tsai YT, Tang L, Banerjee S, Yang J, Nguyen KT. In situ re-endothelialization via multifunctional nanoscaffolds. ACS Nano. 2014;8(10):10826-10836. https://doi.org/10.1021/nn504636n
  48. Mungchan P, Glab-Ampai K, Chruewkamlow N, Trakarnsanga K, Srisawat C, Nguyen KT, Chaicumpa W, Punnakitikashem P. Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention. Molecules. 2022;27(23):8144. https://doi.org/10.3390/molecules27238144
  49. Boos CJ, Balakrishnan B, Jessani S, Blann AD, Lip GY. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction. Chest. 2007;132(6):1920-1926. https://doi.org/10.1378/chest.07-1693
  50. Heper G, Murat SN, Durmaz T, Kalkan F. Prospective evaluation of von Willebrand factor release after multiple and single stenting. Angiology. 2004;55(2):177-186.  https://doi.org/10.1177/000331970405500210
  51. Xier Z, Zhu YX, Tang SW, Kong C, Aili D, Huojia G, Peng H. Plasma VWF: Ag levels predict long-term clinical outcomes in patients with acute myocardial infarction. Front Cardiovasc Med. 2023;9:1013815. https://doi.org/10.3389/fcvm.2022.1013815
  52. Cornelissen A, Vogt FJ. The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement? J Cell Mol Med. 2019;23(1):39-46.  https://doi.org/10.1111/jcmm.13936
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.